-transparent.png){kind=logo}
The cytokinetic effects of carboplatin(CBDCA) on a human ovarian cancer cell line(KF-1) were examined by means of cell survival rate and flow cytometry in comparison with cisplatin(CDDP). CBDCA and CDDP exhibited dose dependent cytotoxicity on KF-1, and CBDCA showed compatible cell growth inhibition to that of 15 times concentration of CDDP in comparison with IC50 of 72 hrs after drug addition. From the analysis of cell cycle, CBDCA and CDDP inhibited cell cycle progression at G2 + M phase. CBDCA exhibited G2 + M phase block to that of 15 to 20 times the concentration of CDDP. We suggested that CBDCA had potential therapeutic activity against ovarian cancer, but should be evaluated carefully in the clinical use.
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
December 1992,
Human cell,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
January 1999,
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
October 1978,
Cancer research,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
December 1986,
Journal of the National Cancer Institute,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
June 1993,
Human cell,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
April 2001,
Gynecologic oncology,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
January 1993,
Annals of oncology : official journal of the European Society for Medical Oncology,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
October 1995,
Seminars in oncology,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
December 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
N Yoshizumi, and
J Fujiwara, and
A Yoshizaki, and
M Sato, and
R Sakai, and
I Nishiya
September 1990,
Gynecologic oncology,
